Serum Level of IL31,33 and 36 in Egyptian Paients With Psoriasis
NCT ID: NCT04344574
Last Updated: 2020-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
90 participants
OBSERVATIONAL
2020-06-01
2021-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To correlate their levels with disease activity using PASI score .
* To allow better understanding of the pathophysiological mechanism of the disease .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
NCT04039451
Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis
NCT03469219
Levels of Pigment Epithelium-derived Factor in Patients With Psoriasis.
NCT05252741
Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity
NCT07001904
Evaluation The Effect of NB-UVB and Methotrexate on The Level of Serum Gelsolin in Psoriatic Patients
NCT06712238
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Assessment of serum interleukin-31 ,33 and 36 concentrations in psoriatic patients Patients and controls Blood samples will collected from psoriatic patients and controls, and will centrifuged for 15 min at 1000 rpm. Next, the serum samples will be subdivided into small aliquots to be stored at -80°C until analysis for cytokine levels. ELISA kits will be used to determine serum IL-31 , 33 and 36
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* healthy volunteers without a family history of psoriasis or other autoimmune disease.
Exclusion Criteria
* cases received glucocorticoids, immunosuppressive drugs at least 1 month before sample collection .
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fatma Elzahraa Adel Ismail
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
interleukins in psoriasis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.